Hikma reported better-than-expected sales in H1, driven by strong growth in Generics and Branded segments. However, with the group largely maintaining its outlook for FY21 (ex. Generics), it points towards sequentially weak H2 21. Additionally, ‘some’ concerns in all its segments made the investors jittery. Having said that, these issues are transient in nature and shouldn’t have any bearing on the group’s longer-term fortunes, and Hikma should return to full throttle, driven by the gradual reco ....
06 Aug 2021
Weaker H2 concerns overshadow strong H1
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Weaker H2 concerns overshadow strong H1
Hikma Pharmaceuticals Plc (HIK:LON) | 1,926 0 0.0% | Mkt Cap: 4,274m
- Published:
06 Aug 2021 -
Author:
Amandeep Goyal -
Pages:
4
Hikma reported better-than-expected sales in H1, driven by strong growth in Generics and Branded segments. However, with the group largely maintaining its outlook for FY21 (ex. Generics), it points towards sequentially weak H2 21. Additionally, ‘some’ concerns in all its segments made the investors jittery. Having said that, these issues are transient in nature and shouldn’t have any bearing on the group’s longer-term fortunes, and Hikma should return to full throttle, driven by the gradual reco ....